Theorem Clinical Research has announced the formation of a strategic alliance with BioTelemetry, Inc.
Theorem Clinical Research
, a clinical research organization specializing in complex trials, has announced the formation of a strategic alliance with BioTelemetry, Inc. (Nasdaq: BEAT). BioTelemetry’s Clinical Research division includes Cardiocore, a global cardiac core laboratory.
“Theorem’s business strategy is to offer our clients the very best in every service area,” said
John Potthoff
, Theorem president and CEO. “BioTelemetry reinforces that strategy with a team of industry-leading scientists, a set of advanced technologies and a broad base of cardiac testing modalities. Theorem clients will benefit from BioTelemetry’s expert consulting services and deep experience across all major therapeutic areas.”
BioTelemetry
CEO Joseph Capper noted, “Theorem’s experience in complex protocols aligns perfectly with our specialized cardiovascular testing services. The partnership complements BioTelemetry’s unique position that spans from clinical research through post-market surveillance and into clinical practice. Both companies support trials in
all clinical phases
of pharmaceutical and biotech development and will collaborate globally within this alliance.”
“Trends in the industry such as safety monitoring boards, translational medicine and risk-based monitoring put additional pressures on the clinical trial process to be faster, safer and more efficient,” said Potthoff. “Our strategic partnership with BioTelemetry allows us to meet — and exceed — those industry standards for our clients.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.